Immunex Overview

  • Year Founded
  • 1981

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 1,618

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $17.8B

Immunex General Information

Description

Operator of a biopharmaceutical company intended to manufacture, develop and market therapeutic products. The company's therapeutic products were essentially immune system proteins that acted as hormones in the body enabling it to offer treatments for cancer, infectious diseases and autoimmune disorders.

Contact Information

Website
www.immunex.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 51 University Street
  • Seattle, WA 98101
  • United States
+1 (206)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Corporate Office
  • 51 University Street
  • Seattle, WA 98101
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 15-Jul-2002 $17.8B Completed Generating Revenue
4. 2PO 13-Nov-2000 Completed Generating Revenue
3. Convertible Debt 20-May-1999 Completed Generating Revenue
2. IPO 01-Jul-1983 $6M Completed Generating Revenue
1. Early Stage VC 01-Jul-1982 $6M $6M Completed Generating Revenue
To view Immunex’s complete valuation and funding history, request access »

Immunex Patents

Immunex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2009140469-A3 Dosage regimen comprising ap02l/trail, anti-vegf / anti-cd20 and chemotherapy to treat nsclc or non-hodgkin's lymphoma, respectively Inactive 14-May-2008
WO-2009140469-A2 Methods of using apo2l/trail to treat cancer Inactive 14-May-2008
CA-2583677-A1 Tnf-like weak inducer of apoptosis (tweak) receptor binding domain Inactive 22-Oct-2004
AU-2005299919-A1 Tweak receptor Active 22-Oct-2004
AU-2005299919-B2 Tweak receptor Inactive 22-Oct-2004 A61K39/3955
To view Immunex’s complete patent history, request access »

Immunex Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunex Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cable & Howse Ventures Venture Capital Minority
Domain Associates Venture Capital Minority
Eurand Corporation Minority
Mayfield Fund Venture Capital Minority
New Enterprise Associates Venture Capital Minority
To view Immunex’s complete investors history, request access »

Immunex FAQs

  • When was Immunex founded?

    Immunex was founded in 1981.

  • Where is Immunex headquartered?

    Immunex is headquartered in Seattle, WA.

  • What is the size of Immunex?

    Immunex has 1,618 total employees.

  • What industry is Immunex in?

    Immunex’s primary industry is Biotechnology.

  • Is Immunex a private or public company?

    Immunex is a Private company.

  • What is the current valuation of Immunex?

    The current valuation of Immunex is .

  • What is Immunex’s current revenue?

    The current revenue for Immunex is .

  • How much funding has Immunex raised over time?

    Immunex has raised $3.24B.

  • Who are Immunex’s investors?

    Cable & Howse Ventures, Domain Associates, Eurand, Mayfield Fund, and New Enterprise Associates have invested in Immunex.

  • When was Immunex acquired?

    Immunex was acquired on 15-Jul-2002.

  • Who acquired Immunex?

    Immunex was acquired by Amgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process